The Overview
argenx SE announced the discontinuation of its Phase 3 UNITY study evaluating efgartigimod subcutaneous (SC) in adults with moderate-to-severe Sjögren's disease. The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility after an interim analysis, concluding that the study was unable to meet its primary endpoint. The safety profile of efgartigimod was consistent with its established profile, with no new safety signals identified. argenx expressed disappointment for patients and committed to a comprehensive analysis of the data to inform future research in this complex autoimmune disease.
Knolens Analysis
At a Glance
| Indication | Sjögren's disease |
| Drug | efgartigimod alfa and hyaluronidase-qvfc |
| Mechanism of Action | FcRn blocker |
| Company | argenx SE |
| Trial Phase | Phase 3 |
| Trial Acronym | UNITY |
| Category | Clinical Trial Event |
| Sub Category | Trial Halted / Terminated |
| Therapeutic Area | Immunology |
| Primary Endpoint | Change from baseline in systemic disease activity, as measured by the clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI), at Week 48 |
| Key Secondary Endpoints | Proportion of patients achieving low disease activity (clinESSDAI <5), responder status on the Sjögren's Tool for Assessing Response (STAR), change in patient-reported symptoms as measured by the Diary of Sjögren's Symptoms Assessment (DiSSA), and safety and tolerability |
| Patient Population Criteria | Adults with moderate-to-severe Sjögren's disease, meeting 2016 ACR/EULAR classification criteria, positive for anti-Ro/SSA autoantibodies, and clinESSDAI ≥6 on stable standard of care |
| Trial Design | Randomized, double-blind, placebo-controlled, multicenter study with an open-label extension |
| Decision Authority | Independent Data Monitoring Committee (IDMC) |
| Combination Drug | recombinant human hyaluronidase PH20 (rHuPH20) |
| Other Approved Indications | Generalized myasthenia gravis (gMG), immune thrombocytopenia (Japan only), chronic inflammatory demyelinating polyneuropathy (CIDP) |
argenx Discontinues Phase 3 UNITY Study for Sjögren's Disease
argenx SE announced the discontinuation of its Phase 3 UNITY study evaluating efgartigimod subcutaneous (SC) in adults with moderate-to-severe Sjögren's disease. The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility after an interim analysis, concluding that the study was unable to meet its primary endpoint. The safety profile of efgartigimod was consistent with its established profile, with no new safety signals identified. argenx expressed disappointment for patients and committed to a comprehensive analysis of the data to inform future research in this complex autoimmune disease.
- The Phase 3 UNITY study of efgartigimod SC in moderate-to-severe Sjögren's disease was discontinued based on an Independent Data Monitoring Committee's (IDMC) recommendation for futility. An interim analysis indicated the study would not meet its primary endpoint, leading to the decision to stop further enrollment and treatment.
- Despite the lack of efficacy, the safety profile observed in the UNITY study was consistent with efgartigimod's known profile, and no new safety signals were identified. This suggests that the drug's safety remains established, even as its efficacy in this specific indication was not demonstrated.
- argenx plans to conduct a comprehensive analysis of the collected data from the UNITY study following database lock. The company aims to gain deeper insights into the study's outcome and the complex biology of Sjögren's disease, intending to share these learnings with the Sjögren's community to potentially inform future research efforts.
Frequently Asked Questions
Why is FcRn inhibition a relevant therapeutic strategy for Sjögren's disease?
Sjögren's disease is an autoimmune condition characterized by chronic inflammation and exocrine gland dysfunction, largely driven by pathogenic IgG autoantibodies. The neonatal Fc receptor (FcRn) plays a crucial role in recycling IgG, preventing its lysosomal degradation and prolonging its half-life. By blocking FcRn, therapies like efgartigimod alfa accelerate the degradation of circulating IgG, including these pathogenic autoantibodies, thereby reducing their levels and mitigating disease activity.
What is the mechanism of action of efgartigimod alfa in autoimmune conditions like Sjögren's disease?
Efgartigimod alfa is a human IgG1 antibody fragment that selectively binds to the neonatal Fc receptor (FcRn). This binding prevents FcRn from recycling endogenous IgG, leading to accelerated degradation of circulating IgG antibodies. By reducing the overall levels of pathogenic IgG, efgartigimod alfa aims to ameliorate the autoimmune response and associated inflammation in diseases such as Sjögren's.
What are the potential benefits of a subcutaneous formulation of efgartigimod alfa with hyaluronidase-qvfc for patients?
The co-formulation with hyaluronidase-qvfc enables subcutaneous administration of efgartigimod alfa, facilitating rapid dispersion and absorption of the drug. This formulation offers significant convenience for patients, potentially allowing for self-administration outside of a clinical setting. It can reduce the burden of intravenous infusions, improving treatment adherence and overall quality of life.
What is the potential role of FcRn inhibitors like efgartigimod alfa in the evolving treatment landscape for Sjögren's disease?
FcRn inhibitors represent a novel therapeutic class for Sjögren's disease, targeting the underlying pathogenic IgG autoantibodies. This approach offers a distinct mechanism compared to current symptomatic treatments or broad immunosuppressants. Efgartigimod alfa and hyaluronidase-qvfc could provide a targeted option for patients with significant autoimmune activity, potentially addressing systemic manifestations and improving glandular function.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
